Ocular Inflammation After Cataract Surgery

• FDA approval · 2024-07-08
  FDA Approved: BROMFENAC OPHTHALMIC SOLUTION, 0.07% — Original Application (Apotex Corp.)

  The FDA approved Apotex Corp.'s generic bromfenac ophthalmic solution 0.07% under an Original Application for relief of ocular pain and redu…

• CLINICAL_TRIALS trial_result · 2023-07-07
  Clinical Trial Update: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study [Phase 3]

  Phase 3 trial evaluating APP13007 for inflammation and pain after cataract surgery with a corneal endothelial cell sub-study; trial complete…

• CLINICAL_TRIALS trial_result · 2023-06-27
  Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery [Phase 2]

  Phase 2 trial evaluating APP13007 for safety, tolerability, and preliminary efficacy in ocular inflammation and pain after cataract surgery …

• FDA approval · 2015-07-01
  FDA Approved: BROMFENAC OPHTHALMIC SOLUTION — Supplemental Application (Bausch & Lomb Americas Inc.)

  The FDA approved a supplemental application for Bromfenac Ophthalmic Solution (bromfenac sodium) from Bausch & Lomb Americas, expanding its …

• FDA approval · 2011-06-27
  FDA Approved: NEVANAC — Supplemental Application (Harrow Eye, LLC)

  FDA approved a supplemental NDA for NEVANAC (nepafenac) submitted by Harrow Eye, LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.